SCHEMBL5427280

SCHEMBL5427280

C[N+](C)(C)CC(CC(=O)[O-])OC(=O)C(O)CC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.61
▸ KMT2A Q03164 4/20 0.61
▸ CYP1A2 P05177 4/20 0.61
▸ HRH1 P35367 1/20 0.61
▸ CYP2C19 P33261 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ LMNA P02545 2/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ SLC25A20 O43772 3/20 0.50
▸ TP53 P04637 3/20 0.50
▸ TSHR P16473 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ CYP2D6 P10635 2/20 0.50
▸ CYP2C9 P11712 2/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16915066 0.84 MEN1 (0.61) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL5085304 0.83 MEN1 (0.59) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL27906323 0.83 LMNA (0.58) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL28581905 0.83 LMNA (0.58) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL3445036 0.82 MEN1 (0.67) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL3445035 0.82 MEN1 (0.67) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL17416718 0.82 MEN1 (0.67) MEN1KMT2ACYP1A2HRH1CYP2C19
Propionyl-Carnitine SCHEMBL15971593 0.81 MEN1 (0.76) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL94489 0.81 MEN1 (0.61) MEN1KMT2ACYP1A2HRH1CYP2C19
SCHEMBL2163305 0.81 MEN1 (0.61) MEN1KMT2ACYP1A2HRH1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384248-A Supermolecule acetyl hexapeptide-8 and preparation method thereof 懿奈(上海)生物科技有限公司 2024-01-12 — — CN claimed
CN-115710533-A Method for extracting wormwood essential oil from supramolecular L-carnitine malate NADES (sodium acetyldes) solvent 深圳市昭德健康科技有限公司 2023-02-24 — — CN claimed
CN-102018655-B Transdermal medicament delivery combined preparation NANOMED SKINCARE INC 2014-04-23 — — CN claimed
CN-102018655-A Transdermal drug delivery combined preparation CHINESE ACAD TECH INST PHYSICS 2011-04-20 — — CN claimed
US-20070072910-A1 Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans NEXGEN PHARMA, INC. 2007-03-29 — — US claimed
US-12441959-B2 Composition containing organic ammonium salt MIYOSHI OIL & FAT CO., LTD. (JP) 2025-10-14 — — US disclosed
CN-117603278-A Method for extracting alkaloid from coptis chinensis by using deep eutectic solvent of L-carnitine and application of method 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) 2024-02-27 — — CN disclosed
CN-117384248-A Supermolecule acetyl hexapeptide-8 and preparation method thereof 懿奈(上海)生物科技有限公司 2024-01-12 — — CN disclosed
CN-115710533-A Method for extracting wormwood essential oil from supramolecular L-carnitine malate NADES (sodium acetyldes) solvent 深圳市昭德健康科技有限公司 2023-02-24 — — CN disclosed
CN-115710533-A Method for extracting wormwood essential oil from supramolecular L-carnitine malate NADES (sodium acetyldes) solvent 深圳市昭德健康科技有限公司 2023-02-24 — — CN disclosed
CN-115710533-A Method for extracting wormwood essential oil from supramolecular L-carnitine malate NADES (sodium acetyldes) solvent 深圳市昭德健康科技有限公司 2023-02-24 — — CN disclosed
WO-2022095337-A1 L-CARNITINE-BASED EMULSION AND PREPARATION METHOD AND DRUG 哈尔滨工业大学(深圳) 2022-05-12 — — WO disclosed
CN-112370423-B L-carnitine-based emulsion, preparation method and medicine 哈尔滨工业大学(深圳) 2021-08-03 — — CN disclosed
CN-112370423-A L-carnitine-based emulsion, preparation method and medicine 哈尔滨工业大学(深圳) 2021-02-19 — — CN disclosed
WO-2020166674-A1 COMPOSITION CONTAINING ORGANIC AMMONIUM SALT ミヨシ油脂株式会社 2020-08-20 — — WO disclosed
US-20140178315-A1 Topical Compositions Comprising Ionic Fluids ARCH CHEMICALS, INC. (US) 2014-06-26 — — US disclosed
WO-2014100633-A1 TOPICAL COMPOSITIONS COMPRISING IONIC FLUIDS ARCH CHEMICALS, INC. (US) 2014-06-26 — — WO disclosed
CN-102018655-B Transdermal medicament delivery combined preparation NANOMED SKINCARE INC 2014-04-23 — — CN disclosed
CN-102018655-A Transdermal drug delivery combined preparation CHINESE ACAD TECH INST PHYSICS 2011-04-20 — — CN disclosed
US-20070072910-A1 Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans NEXGEN PHARMA, INC. 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441959-B2 Composition containing organic ammonium salt SLC6A15, SLC38A7, SLC6A19 MEN1 4282/4885KMT2A 2282/4885CYP1A2 4585/4885
US-20140178315-A1 Topical Compositions Comprising Ionic Fluids KRT18, DSG1, AQP1 MEN1 3532/4885KMT2A 3132/4885CYP1A2 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback